News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diaxonhit Signs a Research Service Agreement With Boehringer Ingelheim Corporation for the Discovery of Novel Epitope Targets in Oncology


9/3/2013 2:27:47 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Diaxonhit (Paris:ALEHT) (Alternext: ALEHT) enters into a research service agreement with Boehringer Ingelheim for the discovery and characterization of novel splice variants that have the potential to be therapeutic targets for oncology. Through the agreement Boehringer Ingelheim secures an option to acquire the rights to research, develop and commercialize, any targets identified using Diaxonhit’s patented SpliceArray™ discovery platform, with the aim of adding further to its comprehensive research programme to develop innovative new cancer drugs.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES